Thyroid Eye Disease Market Size, Share & Trends Analysis Report By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib), By Region, And By Segment Forecasts, 2025-2034

Thyroid Eye Disease Market Size is valued at USD 2.26 billion in 2024 and is predicted to reach USD 4.02 billion by the year 2034 at a 6.0% CAGR during the forecast period for 2025-2034.

Thyroid Eye Disease is an autoimmune condition that causes eye swelling, bulging, and pain, often linked to Graves' disease. Treatments include Tepezza, corticosteroids, and surgery to reduce symptoms like eye bulging and vision problems.

Improved healthcare settings, improvements in autoimmune disease treatment, and positive patient compliance percentage are factors expected to drive the growth of the global Thyroid Eye Disease market. Increasing research & development activities and rising investment are some of the other factors expected to augment the target market growth. The increasing adoption of artificial tears and lubricating eye drops to alleviate dryness and give temporary relief from discomfort globally is expected to boost the market expansion in the coming years.

However, the high cost of Thyroid Eye Disease and lack of a clear thyroid eye treatment, coupled with the COVID-19 outbreak, are factors that may limit growth of the target market during the forecast period. Furthermore, increasing R&D activities, government actions to use sustainable components for production, investments by prominent players are factors expected to create lucrative growth opportunities in terms of revenue for players operating in the global Thyroid Eye Disease market over the forecast period.

Competitive Landscape

Some Major Key Players In The Thyroid Eye Disease Market:

• Horizon Therapeutics
• Viridian Therapeutics
• Pierre Fabre/ACELYRIN
• HanAll Biopharma/Harbour BioMed/Immunovant
• Sling Therapeutics
• Other Market Players

Market Segmentation:

The Thyroid Eye Disease market is segmented on the basis of marketed treatment and pipeline treatment. Based on the marketed treatment, the market is segmented as tepezza (Teprotumumab). By pipeline treatment, the market is segmented into VRDN 001, VB 421, batoclimab, and linsitinib.

Based On Marketed Treatment, The TEPEZZA (Teprotumumab) Segment Is Accounted As A Major Contributor In The Thyroid Eye Disease Market.

The TEPEZZA (Teprotumumab) category is expected to hold a major share of the global Thyroid Eye Disease market in 2023. This is attributed to help in reducing eye bulges and double vision. Additionally, it also decreases the signs and symptoms of thyroid eye disease, including eye pain, edema, and eye disease.

VRDN-001 Segment Witnessed Growth At A Rapid Rate

The VRDN-001 segment is projected to grow at a rapid rate in the global Thyroid Eye Disease market owing to growing use in treating several fatal diseases. The VRDN-001 is an intravenous monoclonal antibody that goals the anti-insulin-like growth factor-1 receptor. The major benefit of using VRDN-001 in treating these diseases is that they are taken from a biological source.          

In The Region, The North America Thyroid Eye Disease Market Holds A Significant Revenue Share.

The North America Thyroid Eye Disease market is expected to report the most increased market share in terms of revenue. This can be attributed to the strong focus on the treatment of thyroid eye disease in the region. In addition, the growing prevalence of several thyroid diseases and advancement in treatment options for Thyroid Eye Disease is also expected to increase the growth of the target market. Growing healthcare setups and rising research and development activities in the region are factors increasing the growth of the target market in the region. In addition, the region Asia Pacific is projected to grow rapidly in the global Thyroid Eye Disease market due to growing concerns about thyroid eye disease, increasing healthcare expenditure, government initiatives, and increasing funding in various industries.

Recent Developments:

• In March 2024, ACELYRIN, INC. announced positive proof-of-concept results from a Phase ½ trial of lonigutamab in thyroid eye condition that is now underway. Lonigutamab is a subcutaneous (SC) humanized IgG1 monoclonal antibody that aims the insulin-like growth factor-1 receptor (IGF-1R), a known mechanism of action for thyroid eye disease treatment.

Thyroid Eye Disease Market Report Scope

Segmentation of Thyroid Eye Disease Market-

Thyroid Eye Disease Market By Marketed Products-

• TEPEZZA (Teprotumumab)

Thyroid Eye Disease Market By Pipeline Treatment-

• VRDN-001
• VB421
• Batoclimab
• Linsitinib)

Thyroid Eye Disease Market By Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa